Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database Academic Article uri icon


MeSH Major

  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Randomized Controlled Trials as Topic


  • In modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.


publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC4482837

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.56.5887

PubMed ID

  • 25385741

Additional Document Info

start page

  • 22

end page

  • 8


  • 33


  • 1